Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...

Today, the American Association for Cancer Research (AACR) released its 14th annual Cancer Progress Report, which provides the latest statistics on cancer incidence, mortality, and survivorship, and ...

Search for other works by this author on: ...

Search for other works by this author on: ...

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

Division of Cell Signaling and Metabolism, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.